Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Recruiting 3Terminated 1Completed 1

Sponsor Class

OTHER 4NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 238Precursor Cell Lymphoblastic Leukemia-Lymphoma 46Recurrence 35Burkitt Lymphoma 23Neoplasms 20Neoplasms, Plasma Cell 17Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Immunoglobulin Light-chain Amyloidosis 13Leukemia 12Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma 10Lymphoma, Large B-Cell, Diffuse 9Lung Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Prostatic Neoplasms 8Leukemia, Biphenotypic, Acute 8Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Breast Neoplasms 7Lymphoma, B-Cell 6Smoldering Multiple Myeloma 5Nausea 5Leukemia, Myeloid, Acute 5Hodgkin Disease 5Brain Neoplasms 5Waldenstrom Macroglobulinemia 4Neoplasm, Residual 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Amyloidosis 4

Interventions

Lenalidomide 7Dexamethasone 5daratumumab 4Calcium Dobesilate 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Curcumin 3isatuximab 2iberdomide 2Leflunomide 2pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1fludarabine phosphate 1fludarabine 1citarinostat 1Watchful Waiting 1Urination 1Stem Cell Transplantation 1Resistance Training 1Propranolol 1Probiotics 1Peripheral Blood Stem Cell Transplantation 1PVX-410 vaccine 1Observation 1Metformin 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Dexamethasone × 1 year × Clear all
NCT04776395 2026-06-01

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Emory University

Phase 2 Recruiting
68 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting
288 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT05288062 2025-08-20

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Mayo Clinic

Phase 2 Terminated
17 enrolled 9 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

NCT02916771 2025-08-11

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Completed
61 enrolled 12 charts
Plasma cell

Smoldering Multiple Myeloma

NCT06762769 2025-08-01

MODIFY

University College, London

Phase 2 Recruiting
63 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡